1 |
Wu, P. C., Lu, J. W., Yang, J. Y., Lin, I. H., Ou, D. L., Lin, Y. H., Chou, K. H., Huang, W. F., Wang, W. P., Huang, Y. L., Hsu, C., Lin, L. I., Lin, Y. M., Shen, C. K. and Tzeng, T. Y. 2014. H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis. Cancer Res. 74, 7333-7343.
DOI
|
2 |
Xu, H., Zhang, R., Li, X., Liu, Z., Wang, Y. and Zhang, H. 2020. EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress. Cancer Cell Int. 20, 175.
DOI
|
3 |
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R. and Gu, W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283.
DOI
|
4 |
Liu, S., Luan, J. and Ding, Y. 2018. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to suppress proliferation, migration, and invasion of PANC-1 pancreatic cancer cells. Oncol. Res. 26, 683-690.
DOI
|
5 |
Na, H. H., Kang, Y. S. and Kim, K. C. 2017. Cloning and activity analysis of the FosB promoter region from human genomic DNA. J. Life Sci. 27, 857-863.
DOI
|
6 |
Seoane, J., Le, H. and Massague, J. 2002. Myc suppression of the p21 Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734.
DOI
|
7 |
Shahzad, M. M., Arevalo, J. M., Armaiz-Pena, G. N., Lu, C., Stone, R. L., Moreno-Smith, M., Nishimura, M., Lee, J. W., Jennings, N. B., Bottsford-Miller, J., Vivas-Mejia, P., Lutgendorf, S. K., Lopez-Berestein, G., Bar-Eli, M., Cole, S. W. and Sood, A. K. 2010. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J. Biol. Chem. 285, 35462-35470.
DOI
|
8 |
Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M. and Krammer, P. H. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045.
DOI
|
9 |
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J. and Strasser, A. 2018. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 25, 104-113.
DOI
|
10 |
Bamberger, A., Methner, C., Lisboa, B. W., Stadtler, C. H., Schulte, M., Loning, T. and Milde Langosch, K. 1999. Expression pattern of the AP 1 family in breast cancer: Association of fosB expression with a well differentiated, receptor positive tumor phenotype. Int. J. Cancer 84, 533-538.
DOI
|
11 |
Barrett, C. S., Millena, A. C. and Khan, S. A. 2017. TGF-β effects on prostate cancer cell migration and invasion require FosB. Prostate 77, 72-81.
DOI
|
12 |
Sun, Q., Ding, L., Xiao, J., Chien, W., Lim, S., Hattori, N., Goodglick, L., Chia, D., Mah, V. and Alavi, M. 2015. SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. J. Pathol. 235, 559-570.
DOI
|
13 |
Michael, D. and Oren, M. 2003. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13, 49-58.
DOI
|
14 |
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H., Liebermann, D. A., Hoffman, B. and Reed, J. C. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
|
15 |
Siderovski, D. P., Blum, S., Forsdyke, R. E. and Forsdyke, D. R. 1990. A set of human putative lymphocyte G0/G1 switch genes includes genes homologous to rodent cytokine and zinc finger protein-encoding genes. DNA Cell Biol. 9, 579-587.
DOI
|
16 |
Sun, Y., Wei, M., Ren, S. C., Chen, R., Xu, W. D., Wang, F. B., Lu, J., Shen, J., Y. Yu, W. J., Hou, G., Xu, C. L., Huang, J. T. and Sun, Y. H. 2014. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J. Androl. 16, 319-324.
DOI
|
17 |
Wisdom, R. and Verma, I. M. 1993. Proto-oncogene FosB: the amino terminus encodes a regulatory function required for transformation. Mol. Cell Biol. 13, 2635-2643.
DOI
|
18 |
Surget, S., Khoury, M. P. and Bourdon, J. C. 2013. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 7, 57-68.
|
19 |
Toufektchan, E. and Toledo, F. 2018. The guardian of the genome revisited: p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure. Cancers (Basel) 10, 135.
DOI
|
20 |
Williams, A. B. and Schumacher, B. 2016. p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med. 6, 10.
|
21 |
Nihira, N. T., Ogura, K., Shimizu, K., North, B. J., Zhang, J., Gao, D., Inuzuka, H. and Wei, W. 2017. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci. Signal. 10, 1126.
|
22 |
Na, H. H., Noh, H. J., Cheong, H. M., Kang, Y. S. and Kim, K. C. 2016. SETDB1 mediated FosB expression increases the cell proliferation rate during anticancer drug therapy. BMB. Rep. 49, 238-243.
DOI
|
23 |
Nestler, E. J. 2004. Molecular mechanisms of drug addiction. J. Neurosci. 47, 24-32.
|
24 |
Nestler, E. J. and Malenka, R. C. 2004. The addicted brain. Sci. Am. 290, 78-85.
DOI
|
25 |
Noh, H., Kim, K., Cho, H., Chang, Y., Jang, W. H., Seog, D., Kim, J., Kim, B., Kwon, H. and Kim, Y. 2014. Promoter cloning of human SETDB1 gene utilizing bioinformatic programs. J. Life Sci. 24, 1-7.
DOI
|
26 |
Noh, H. J, Kim, K. A. and Kim, K. C. 2014. p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death. Biochem. Biophys. Res. Commun. 446, 43-48.
DOI
|
27 |
Fridman, J. S. and Lowe, S. W. 2003. Control of apoptosis by p53. Oncogene 22, 9030-9040.
DOI
|
28 |
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J. and Ferre, F. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517.
DOI
|
29 |
Donehower, L. A. 2014. Phosphatases reverse p53-mediated cell cycle checkpoints. Proc. Natl. Acad. Sci. USA. 111, 7172-7173.
DOI
|
30 |
Fei, Q., Shang, K., Zhang, J., Chuai, S., Kong, D., Zhou, T., Fu, S., Liang, Y., Li, C. and Chen, Z. 2015. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat. Commun. 6, 1-12.
|
31 |
Guo, J., Dai, X., Laurent, B., Zheng, N., Gan, W., Zhang, J., Guo, A., Yuan, M., Liu, P. and Asara, J. M. 2019. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat. Cell Biol. 21, 226-237.
DOI
|
32 |
Han, E. S., Muller, F. L., Perez, V. I., Qi, W., Liang, H., Xi, L., Fu, C., Doyle, E., Hickey, M., Cornell, J., Epstein, C. J., Roberts, L. J., Van Remmen, H. and Richardson, A. 2008. The in vivo gene expression signature of oxidative stress. Physiol. Genomics 34, 112-126.
DOI
|
33 |
Lee, J. and Kim, K. 2013. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem. Biophys. Res. Commun. 438, 647-652.
DOI
|
34 |
Ruffle, J. K. 2014. Molecular neurobiology of addiction: what's all the (Δ) FosB about? Am. J. Drug Alcohol Abuse 40, 428-437.
DOI
|